Green light in EU for Novartis’ Cosentyx
The European Commission (EC) has approved Novartis’ Cosentyx (secukinumab) for the treatment of people living with ankylosing spondylitis (AS) and psoriatic arthritis (PsA). For AS.
Pharmaceuticals, Biotechnology and Life Sciences
The European Commission (EC) has approved Novartis’ Cosentyx (secukinumab) for the treatment of people living with ankylosing spondylitis (AS) and psoriatic arthritis (PsA). For AS.
The Swiss-based company Geistlich Pharma AG is recalling batch of Decalcit, vitamin D and calcium chewable tablets, from the market.
Biosense Webster has acquired Coherex Medical, Inc. a privately held medical device company based in Salt Lake City, Utah.
Janssen Research & Development, LLC has submitted to the U.S. Food and Drug Administration (FDA) a New Drug Application (NDA) for Invokamet extended release (XR).
Bayer has submitted an application for marketing authorization in both the European Union and in the United States for LCS-16, a new low-dose levonorgestrel-releasing intrauterine system
Sanofi and AstraZeneca have announced a direct exchange of 210,000 compounds from their respective, proprietary compound libraries.
Mylan’s subsidiaries were sued Warner Chilcott and Qualicaps in connection with the filing of an ANDA with the FDA for Mesalamine Delayed-release Capsules.
The Food and Drug Administration (FDA) revealed Thursday latest products it had found containing hidden drug ingredients.
The prescriber certification deadline for new Clozapine REMS Program has been extended from November 23 to December 14. Due to…
The Food and Drug Administration (FDA) has issued a notice in which it advises consumers not to purchase or use XForMan Plus,…